SUMMARY
Long non-coding RNA (lncRNA) signatures have emerged as important prognostic biomarkers in acute myeloid leukaemia (AML), stratifying patients into high-risk and low-risk groups and thus providing valuable insights for personalised treatment strategies. The development of these signatures often involves comprehensive bioinformatics analyses, employing various statistical methods to ensure robustness and accuracy. Nevertheless, many reports are flawed by the presence of specific biases and/or incompleteness. Here we performed a comprehensive review of recently identified prognostic lncRNA signatures in AML, including our own report on a 69-lncRNA signature predicting relapse-free survival in paediatric acute myeloid leukaemia. Next to their predictive impact, we provide insights into their strengths and shortcomings.
(BELG J HEMATOL 2025;16(2):54–64)
